Bio/Pharmaceutical Analysis Techniques

Sartorius and Waters will collaborate to develop integrated analytical solutions for downstream biomanufacturing.

The Agilent 8697 Headspace Sampler-XL Tray has a 120-vial capacity.

Mass spectrometric techniques are providing insights in critical RNA-based therapeutic areas.

The collaboration will see Shimadzu and UMG develop new clinical laboratory methods using LC-MS for TDM analysis.

Analyzing elemental impurities in drug products is—much like other analytical testing—primarily aimed at ensuring patient safety.

Fresh insight is instrumental in the discussion of novel analytics.

The Thermo Scientific Ramina Process Analyzer is designed with user ease at the forefront.

Thermo Fisher and Symphogen have extended their collaboration involving improved data workflow, which supports the discovery and development of new cancer treatments.

The acquisition and analysis of MS data can be made more efficient with the integration of modern software tools.

A new portfolio of chromatography and mass spectrometry consumables launched by Thermo Fisher Scientific is designed to meet higher performance requirements while remaining economical.

The partnership between Waters and Sartorius aims to accelerate speed and increase accuracy in bioprocessing analysis.

Thermo Fisher Scientific showcases its new mass spectrometry and chromatography solutions at the ASMS Conference on Oct. 31–Nov. 4, 2021.

CuriRx’s CuriLytics platform is a mass spectrometry instrument that will support complex biotherapeutics development.

Intelligent analytical tools detect impurities to help ensure the quality of small-molecule drug ingredients.

New challenges arise in extractable and leachable studies for cell and gene therapy products.

Mass spectrometry and automation are growing in importance for protein characterization, but further improvements are still needed.

A well-chosen replication strategy can effectively reduce the uncertainty for an analytical method, enabling appropriate decisions regarding pharmaceutical quality.

Raman spectroscopy delivers real time, non-destructive process insights for critical process parameters to monitor pharmaceutical manufacturing.

The need for real-time monitoring and control has spurred the development of new analytical tools.

Common approaches to analyze elemental impurities for compliance with regulatory requirements are robust but still have some limitations.

Having a clear and detailed understanding of exactly what a biomolecule entails is essential for therapeutics development.

The £500,000 (US$686,294)-investment in mass spectrometry support will accelerate biologics development and approval.

Enhanced sensitivity and ultra-high detection speed provide improved robustness and operability.

The new filters extend column life and reduce contamination while simplifying sample preparation.

The new chromatography columns provide enhanced separation for high order aggregates and macromolecules.

Complex protein structures pose analytical challenges that can be addressed by advanced mass spectrometry technologies and workflows, which can be used to comprehensively characterize them.

As equipment evolves and use of PAT increases, DOE is becoming an integral part of upstream bioprocess development.

The company is expanding its bioanalytical capacity and capabilities to support biologic drug development, cell and gene therapy development, and biomarker analysis.

EMA plans to issue new guidance, as US and European regulators respond to reports of nitrosamine contamination in H2 blockers, including Zantac, that contain rantidine.

Protagen Protein Services’ recently acquired Brucker Tensor II IR spectrometer significantly expands the company’s analytical capabilities.